Publications by authors named "S Courby"
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Lydia Roy Jean-Claude Chomel Joëlle Guilhot Agnès Guerci-Bresler Martine Escoffre-Barbe Stéphane Courby
Br J Haematol
January 2023
Article Synopsis
- * A total of 79 patients participated, and the primary goal was to assess the cumulative molecular response rates over 12 months, with results showing significant rates of deep molecular response at 5 years.
- * While grade 3 neutropenia was common, it didn't lead to severe infections, and most patients continued the Peg-IFN treatment for a substantial time, resulting in notable molecular response rates after 12 and 24 months.
Article Synopsis
- Momelotinib, a JAK1 and JAK2 inhibitor, was tested in a phase 2 study for treating polycythemia vera (PV) and essential thrombocythemia (ET), focusing on oral doses of 100mg and 200mg.
- Out of 39 enrolled patients, only 2 (5.1%) met the study's primary efficacy endpoint, leading to the termination of the study due to limited effectiveness.
- Adverse events related to momelotinib were common, affecting 79.5% of participants, with headaches, dizziness, and fatigue being the most frequent; there were also some serious adverse events.
The optimal management of relapsed diffuse large B-cell lymphoma (DLBCL) is not standardized. The Groupe Ouest Est des Leucémies et aAutres Maladies du Sang developed a combination of vinorelbine, ifosfamide, mitoxantrone and prednisone (NIMP) for the treatment of relapsed DLBCL, and assessed its efficacy and safety in association with rituximab (R). This multicentric phase II study included 50 patients with DLBCL in first relapse, aged 18-75 years.
View Article and Find Full Text PDF